Search research articles
Contact Us
Filters
Showing results (21-30 of 119) with videos related to
Page
of 12
Sort By:
The Journal of Infectious Diseases
|
July 12, 2011
Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate
Kathryn B Anderson, Robert V Gibbons, Robert Edelman, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association
|
April 29, 2020
Closer and closer? Maternal immunization: current promise, future horizons
Cyril Engmann, Jessica A Fleming, Sadaf Khan, et al.
The Pediatric Infectious Disease Journal
|
November 12, 2014
Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age
Miguel A Rodriguez Weber, Carine Claeys, Carlos Aranza Doniz, et al.
The Journal of Infectious Diseases
|
October 9, 2014
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial
Pope Kosalaraksa, Robert Jeanfreau, Louise Frenette, et al.
Human Vaccines
|
October 3, 2006
Rapid licensure of a new, inactivated influenza vaccine in the United States
John J Treanor, James D Campbell, Rebecca C Brady, et al.
The American Journal of Tropical Medicine and Hygiene
|
January 27, 2004
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys
Kenneth H Eckels, Doria R Dubois, Robert Putnak, et al.
Clinical and Diagnostic Laboratory Immunology
|
September 3, 2002
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M
Jitvimol Seriwatana, Mrigendra P Shrestha, Robert M Scott, et al.
The Journal of Infectious Diseases
|
September 10, 2016
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
Anuradha Madan, Nathan Segall, Murdo Ferguson, et al.
Human Vaccines & Immunotherapeutics
|
December 9, 2014
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials
David W Vaughn, Harry Seifert, Anne Hepburn, et al.
Vaccine
|
March 18, 2017
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial
Anuradha Madan, Murdo Ferguson, Paul Rheault, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 119) with videos related to
Sort By:
Page
of 12
The Journal of Infectious Diseases
|
July 12, 2011
Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate
Kathryn B Anderson, Robert V Gibbons, Robert Edelman, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association
|
April 29, 2020
Closer and closer? Maternal immunization: current promise, future horizons
Cyril Engmann, Jessica A Fleming, Sadaf Khan, et al.
The Pediatric Infectious Disease Journal
|
November 12, 2014
Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age
Miguel A Rodriguez Weber, Carine Claeys, Carlos Aranza Doniz, et al.
The Journal of Infectious Diseases
|
October 9, 2014
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial
Pope Kosalaraksa, Robert Jeanfreau, Louise Frenette, et al.
Human Vaccines
|
October 3, 2006
Rapid licensure of a new, inactivated influenza vaccine in the United States
John J Treanor, James D Campbell, Rebecca C Brady, et al.
The American Journal of Tropical Medicine and Hygiene
|
January 27, 2004
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys
Kenneth H Eckels, Doria R Dubois, Robert Putnak, et al.
Clinical and Diagnostic Laboratory Immunology
|
September 3, 2002
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M
Jitvimol Seriwatana, Mrigendra P Shrestha, Robert M Scott, et al.
The Journal of Infectious Diseases
|
September 10, 2016
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
Anuradha Madan, Nathan Segall, Murdo Ferguson, et al.
Human Vaccines & Immunotherapeutics
|
December 9, 2014
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials
David W Vaughn, Harry Seifert, Anne Hepburn, et al.
Vaccine
|
March 18, 2017
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial
Anuradha Madan, Murdo Ferguson, Paul Rheault, et al.
Page
of 12